View Item 

Show simple item record

The Role of Helicobacter pylori in Peptic Ulcer Disease

dc.contributor.authorPartipilo, Maria L.en_US
dc.contributor.authorWoster, Patricia S.en_US
dc.date.accessioned2012-03-16T15:59:15Z
dc.date.available2012-03-16T15:59:15Z
dc.date.issued1993-07-08en_US
dc.identifier.citationPartipilo, Maria L.; Woster, Patricia S. (1993). "The Role of Helicobacter pylori in Peptic Ulcer Disease." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 13(4). <http://hdl.handle.net/2027.42/90299>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90299
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.titleThe Role of Helicobacter pylori in Peptic Ulcer Diseaseen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumCollege of Pharmacy, University of Michigan, and the Department of Pharmacy Services, University of Michigan Medical Center, Ann Arbor, Michigan.en_US
dc.identifier.pmid8361859en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90299/1/j.1875-9114.1993.tb02740.x.pdf
dc.identifier.doi10.1002/j.1875-9114.1993.tb02740.xen_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceMainguet P, Delmee M, Debongnie JC. Omeprazole, Campylobacter pylori and duodenal ulcer. Lancet. 1989; 2: 389 – 90.en_US
dc.identifier.citedreferenceWeil J, Bell GD, Powell K et al. Omeprazole and Helicobacter pylori: temporary suppression rather than true eradication. Aliment Pharmacol Ther 1991; 5: 309 – 13.en_US
dc.identifier.citedreferenceDaw MA, Deegan P, Leen E, O'Morain C. Short report: the effect of omeprazole on Helicobacter pylori and associated gastritis. Aliment Pharmacol Ther 1991; 5: 435 – 9.en_US
dc.identifier.citedreferenceGorbach SL. Bismuth therapy in gastrointestinal diseases. Gastroenterology 1990; 99: 863 – 75.en_US
dc.identifier.citedreferenceBurns R, Thomas DW, Barron VJ. Reversible encephalopathy possibly associated with bismuth subgallate ingestion. Br Med J 1974; 1: 220 – 3.en_US
dc.identifier.citedreferenceMarshall BJ, Armstrong JA, Francis GJ et al. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis. Digestion 1987; 37 ( suppl 2 ): 16 – 30.en_US
dc.identifier.citedreferenceBorsch G, Mai U, Muller KM. Monotherapy of polychemotherapy in the treatment of Campylobacter pylori ‐related gastroduodenal disease. Scand J Gastroenterol 1988; 142 ( suppl ): 101 – 6.en_US
dc.identifier.citedreferenceMarshall BJ. The use of bismuth in gastroenterology. Am J Gastroenterol 1991; 86: 16 – 25.en_US
dc.identifier.citedreferenceWeller MPJ. Neuropsychiatric symptoms following bismuth intoxication. Postgrad Med J 1988; 64: 308 – 10.en_US
dc.identifier.citedreferenceBeckingham IJ, Baird G, Kesteven PJL. Acute thrombocytopenia after De‐Nol. Gut 1989; 30: 1016 – 17.en_US
dc.identifier.citedreferenceBorsch G, Mai U, Opferkuch W. Oral triple therapy (OTT) may effectively eradicate Campylobacter pylori in man: a pilot study [abstr]. Gastroenterology 1988; 94: a44.en_US
dc.identifier.citedreferenceBorody T, Cole P, Noonan S et al. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust 1989; 151: 431 – 5.en_US
dc.identifier.citedreferenceGraham DY, Lew GM, Evans DG et al. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. Ann Intern Med 1991; 115: 266 – 9.en_US
dc.identifier.citedreferenceGraham DY, Lew GM, Klein PD et al. Effect of treatment of Helicobacter pylori infection on the long‐term recurrence of gastric or duodenal ulcer. Ann Intern Med 1992; 116: 705 – 8.en_US
dc.identifier.citedreferenceCoelho LGV, Passos MDF, Chausson Y et al. Five‐day bismuth‐free triple therapy for the eradication of Helicobacter pylori and reduction of duodenal ulcer relapse. Am J Gastroenterol 1991; 86: 971 – 5.en_US
dc.identifier.citedreferencePewett EJ, Nwokolo CU, Hudson M et al. The effect of GR122311X, a bismuth compound with H2‐antagonist activity, on 24‐hour intragastric acidity. Aliment Pharmacol Ther 1991; 5: 481 – 90.en_US
dc.identifier.citedreferenceGlupczynski Y, Burrette A. On the who's and when's of therapy for Helicobacter pylori [letter]. Am J Gastroenterol 1991; 86: 924 – 5.en_US
dc.identifier.citedreferenceBardhan K, Cole DS, Hawkins BW et al. Does treatment with cimetidine extended beyond initial healing of duodenal ulcer reduce the subsequent relapse rate? Br Med J 1982; 284: 621 – 3.en_US
dc.identifier.citedreferenceChamberlain CE, Peura DA. Campylobacter ( Helicobacter) pylori: is peptic disease a bacterial infection? Arch Intern Med 1990; 150: 951 – 5.en_US
dc.identifier.citedreferenceBoyd EJS, Penston JG, Johnston DA et al. Does maintenance therapy keep duodenal ulcers healed? Lancet 1988; 1: 1324 – 7.en_US
dc.identifier.citedreferenceMarshall BJ, McGechie DB, Rogers PA et al. Pyloric Campylobacter infection and gastroduodenal disease. Med J Aust 1985; 142: 439 – 44.en_US
dc.identifier.citedreferencePeterson WL. Helicobacter pylori and peptic ulcer disease. N Engl J Med 1991; 324: 1043 – 8.en_US
dc.identifier.citedreferenceOrmand JE, Talley NJ. Helicobacter pylori: controversies and an approach to management. Mayo Clin Proc 1990; 65: 414 – 26.en_US
dc.identifier.citedreferenceWarren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 1: 1273 – 5.en_US
dc.identifier.citedreferenceGoodwin CS, McCulloch RK, Armstrong JA et al. Unusual cellular fatty acids and distinctive ultrastructure in a new spiral bacterium ( Campylobacter pyloridis ) from the human gastric mucosa. J Med Microbiol 1985; 19: 257 – 67.en_US
dc.identifier.citedreferenceGoodwin CS, Armstrong JA, Marshall BJ. Campylobacter pyloridis, gastritis, and peptic ulceration. J Clin Pathol 1986; 39: 353 – 65.en_US
dc.identifier.citedreferenceRomaniuk PJ, Zoltowska B, Trust TJ et al. Campylobacter pylori, the spiral bacterium associated with human gastritis, is not a true Campylobacter sp. J Bacteriol 1987; 169: 2137 – 41.en_US
dc.identifier.citedreferenceGoodwin CS, Gordon A, Burke V. Helicobacter pylori ( Campylobacter pylori ) and duodenal ulcer. Med J Aust 1990; 153: 66 – 7.en_US
dc.identifier.citedreferenceSidebotham RL, Baron JH. Hypothesis: Helicobacter pylori, urease, mucus, and gastric ulcer. Lancet 1990; 335: 193 – 5.en_US
dc.identifier.citedreferenceWyle FA. Helicobacter pylori: current perspectives. J Clin Gastroenterol 1991; 13 ( suppl ): S114 – 24.en_US
dc.identifier.citedreferenceMaddocks AC. Helicobacter pylori (formerly Campylobacter pyloridis/pylori ) 1986–1989: a review. J Clin Pathol 1990; 43: 353 – 6.en_US
dc.identifier.citedreferenceKorman MG. Helicobacter pylori: fact or fiction? Scand J Gastroenterol 1990; 25 ( suppl 175 ): 159 – 65.en_US
dc.identifier.citedreferenceBarthel JS, Westblom JU. Gastritis and Campylobacter pylori in healthy, asymptomatic volunteers. Arch Intern Med 1988; 148: 1149 – 51.en_US
dc.identifier.citedreferenceRauws EAJ, Langenberg W, Houthoff HJ et al. Campylobacter pyloridis ‐associated chronic active antral gastritis: a prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 1988; 94: 33 – 40.en_US
dc.identifier.citedreferenceMorris A, Nicholson G, Lloyd G et al. Seroepidemiology of Campylobacter pyloridis. N Z Med J 1986; 99: 657 – 9.en_US
dc.identifier.citedreferenceMarshall BJ, McGechie DB, Francis GJ et al. Pyloric Campylobacter serology [letter]. Lancet 1984; 2: 281.en_US
dc.identifier.citedreferenceRawles JW, Paull G, Yardley JH et al. Gastric Campylobacter ‐like organisms (CLO) in a US hospital population [abstr]. Gastroenterology 1986; 90: 1599.en_US
dc.identifier.citedreferenceLandenberg W, Rauws EAJ, Oudbier JH et al. Patient‐to‐patient transmission of Campylobacter pylori infection by fiberoptic gastroduodenoscopy and biopsy. J Infect Dis 1990; 161: 507 – 11.en_US
dc.identifier.citedreferenceMitchell HM, Lee A, Carrick J. Increased incidence of Campylobacter pylori infection in gastroenterologists: further evidence to support person‐to‐person transmission of C. pylori.. Scand J Gastroenterol 1989; 24: 396 – 400.en_US
dc.identifier.citedreferenceBlaser MJ. Epidemiology and pathophysiology of Campylobacter pylori infections. Rev Infect Dis 1990; 12 ( suppl 1 ): S99 – 106.en_US
dc.identifier.citedreferenceGoodman LJ, Lisowski JM. Helicobacter pylori and the upper GI tract: a bug for all lesions? Hosp Formulary 1991; 26: 792 – 800.en_US
dc.identifier.citedreferenceSoll AH. Pathogenesis of peptic ulcer and implications for therapy. N Engl J Med 1990; 322: 909 – 16.en_US
dc.identifier.citedreferenceBlaser M. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis 1990; 161: 626 – 33.en_US
dc.identifier.citedreferenceLevi S, Beardshall K, Haddad G et al. Campylobacter pylori and duodenal ulcers: the gastrin link. Lancet 1989; 1: 1167 – 8.en_US
dc.identifier.citedreferenceClearfield HR. Helicobacter pylori: aggressor or innocent bystander? Med Clin North Am 1991; 75: 815 – 29.en_US
dc.identifier.citedreferenceLambert JR, Dunn KL, Turner H et al. Effect of histological gastritis following eradication of Campylobacter pyloridis. Gastroenterology 1986; 90: 1509.en_US
dc.identifier.citedreferenceMcNulty CAM, Gearty JC, Crump B et al. Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J 1986; 293: 645 – 9.en_US
dc.identifier.citedreferenceMorris A, Nicholson G. Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 1987; 82: 192 – 9.en_US
dc.identifier.citedreferenceLoffeld RJLF. Helicobacter pylori in gastroduodenal disease. Pharm Weekbl [Sci] 1990; 12: 46 – 50.en_US
dc.identifier.citedreferenceMcKinlay AW, Upadhyay R, Gemmell CG et al. Helicobacter pylori: bridging the credibility gap. Gut 1990; 31: 940 – 5.en_US
dc.identifier.citedreferenceCoghlan JG, Humphries H, Dooley C et al. Campylobacter pylori and recurrence of duodenal ulcers. Lancet 1987; 1: 1109 – 11.en_US
dc.identifier.citedreferenceRauws EAJ, Tytgat GNJ. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990; 335: 1233 – 5.en_US
dc.identifier.citedreferenceMarshall BJ, Goodwin CS, Warren JR et al. Prospective double‐blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988; 2: 1437 – 42.en_US
dc.identifier.citedreferenceDiaz MQ, Escobar AS. Metronidazole versus cimetidine in treatment of gastroduodenal ulcer [letter]. Lancet 1986; 1: 907.en_US
dc.identifier.citedreferenceLambert JR, Borromeo M, Korman MG et al. Effect of colloidal bismuth (De‐Nol) on healing and relapse of duodenal ulcers: role of Campylobacter pyloridis [abstr]. Gastroenterology 1987; 92: 1489.en_US
dc.identifier.citedreferenceBader JP. The safety profile of De‐Nol. Digestion 1987; 37 ( suppl 2 ): 53 – 9.en_US
dc.identifier.citedreferenceLind CD, Blaser MJ. Helicobacter pylori and duodenal ulceration. Hosp Pract 1991; 26 ( 2A ): 45 – 63.en_US
dc.identifier.citedreferenceLoffeld RJ, Potters HV, Stobberingh E et al. Campylobacter associated gastritis in patients with non‐ulcer dyspepsia: a double blind placebo controlled trial with colloidal bismuth subcitrate. Gut 1989; 30: 1206 – 12.en_US
dc.identifier.citedreferenceRokkas T, Pursey C, Uzoechina E et al. Non‐ulcer dyspepsia and short term De‐Nol therapy: a placebo controlled trial with particular reference to the role of Campylobacter pylori. Gut 1988; 29: 1386 – 91.en_US
dc.identifier.citedreferenceLambert JR, Dunn K, Borromeo M et al. Campylobacter pylori. A role in non‐ulcer dyspepsia? Scand J Gastroenterol 1989; 160 ( suppl ): 7 – 13.en_US
dc.identifier.citedreferenceKang Y, Tay HH, Wee A et al. Effect of colloidal bismuth subcitrate on symptoms and gastric histology in non‐ulcer dyspepsia. A double blind placebo controlled study. Gut 1990; 31: 476 – 80.en_US
dc.identifier.citedreferenceMorgan D, Kraft W, Bender M et al. Nitrofurans in the treatment of gastritis associated with Campylobacter pylori. Gastroenterology 1988; 95: 1178 – 84.en_US
dc.identifier.citedreferenceGlupczynski Y, Burett A, Labbe M et al. Campylobacter pylori ‐associated gastritis: a double‐blind placebo‐controlled trial with amoxycillin. Am J Gastroenterol 1988; 83: 365 – 72.en_US
dc.identifier.citedreferenceGraham DY, Borsch GMA. The who's and when's of therapy for Helicobacter pylori. Am J Gastroenterol 1990; 85: 1552 – 5.en_US
dc.identifier.citedreferenceO'Riordan T, Mathai E, Tobin E et al. Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate. Gut 1990; 31: 999 – 1002.en_US
dc.identifier.citedreferenceWeil J, Bell GD, Powell K et al. Helicobacter pylori infection treated with a tripotassium dicitrate bismuthate and metronidazole combination. Aliment Pharmacol Ther 1990; 4: 651 – 7.en_US
dc.identifier.citedreferenceGlupczynski Y, Burette A. Drug therapy for Helicobacter pylori infection: problems and pitfalls. Am J Gastroenterol 1990; 85: 1545 – 51.en_US
dc.identifier.citedreferenceWestblom TU, Duriex DE. Enhancement of antibiotic concentrations in gastric mucosa by H2‐receptor antagonist: implications for treatment of Helicobacter pylori infections. Dig Dis Sci 1991; 36: 25 – 8.en_US
dc.identifier.citedreferenceHui WM, Lam SK, Ho J et al. Effect of omeprazole on duodenal ulcer‐associated antral gastritis and Helicobacter pylori. Dig Dis Sci 1991; 36: 577 – 82.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1875-9114.1993.tb02740.x.pdf
Size:
954.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.